Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification

This article was originally published in The Pink Sheet Daily

Executive Summary

Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.


Related Content

New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
Teva Buys Majority Stake In Japanese Generics Company For $460 Mil.
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Teva Stakes OTC Claim With P&G Joint Venture
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts